Metabolomic Profiling in Glioma Dynamics

Metabolomic profiling has emerged as a powerful approach for characterising the small-molecule complement of glioma cells and their microenvironment, revealing dynamic alterations in energy, lipid and amino acid pathways that underpin tumour growth, invasion and therapeutic resistance. In gliomas, hallmark shifts such as enhanced glycolysis despite adequate oxygen (the Warburg effect), reconfigured tricarboxylic acid cycle flux and aberrant lipid biosynthesis support rapid proliferation and adaptation to hypoxia. Metabolite signatures in tumour tissue, blood plasma and cerebrospinal fluid reflect both intrinsic genomic features—such as isocitrate dehydrogenase mutations—and extrinsic influences including microvascular perfusion and immune cell infiltration. Advances in high-resolution mass spectrometry and nuclear magnetic resonance spectroscopy, combined with targeted and untargeted workflows, enable the detection of dozens to hundreds of metabolites in parallel. Integration of longitudinal metabolomic data with genomic and transcriptomic profiles lays the groundwork for stratifying glioma subtypes, tracking disease progression and identifying novel biomarkers for early detection, prognosis and therapeutic vulnerability. As the field moves towards clinical translation, metabolomic markers in liquid biopsies promise minimally invasive tools for monitoring treatment response and predicting relapse, while metabolic interventions offer a route to disrupt tumour-specific pathways without compromising normal brain function.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Metabolomic Profiling in Glioma Dynamics publication trend

The graph below shows the total number of articles in metabolomic profiling in glioma dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolomics: The large-scale study of small molecules (metabolites) within cells, tissues or biofluids to characterise metabolic states.

Glioma: A type of primary brain tumour arising from glial cells, graded by malignancy from low grade to glioblastoma.

Cerebrospinal fluid (CSF): The clear fluid surrounding the brain and spinal cord, used for detecting central nervous system metabolites.

Liquid biopsy: A minimally invasive assay of biofluids (e.g., blood, CSF) to monitor tumour-derived biomarkers.

Warburg effect: The propensity of cancer cells to favour glycolysis over oxidative phosphorylation even under normoxic conditions.

Mass spectrometry: An analytical technique that measures mass-to-charge ratios of ionised compounds to identify and quantify metabolites.

IDH mutation: A genetic alteration in isocitrate dehydrogenase enzymes that produces the oncometabolite D-2-hydroxyglutarate in gliomas.

References

1. Altered plasma metabolite levels can be detected years before a glioma diagnosis. JCI Insight (2023).
2. The genomic alterations in glioblastoma influence the levels of CSF metabolites. Acta Neuropathologica Communications (2024).
3. Alterations in cellular metabolism under different grades of glioma staging identified based on a multi-omics analysis strategy. Frontiers in Endocrinology (2023).